All In Biotech

Drug Trial Radar · NCT01977209

Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression

A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression

Last checked: Nov 19, 2026Latest source record: Nov 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

204

Planned (sponsor's estimate)

Start

Sep 2013

Primary completion

Feb 2016

Study completion Sep 2016

Sponsor

Lead sponsor
Third Military Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 6, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators' experimental study found that gossypol was the natural inhibitor of apyrimidinic endonuclease 1 (APE1) and clinical study observed that high expression of APE1 was relative to the platinum-resistance in non-small cell lung cancer. Thus the purpose of this study is to find out whether gossypol can improve the sensitivity of cisplatin-based chemotherapy in the non-small cell lung cancer with apurinic apyrimidinic endonuclease 1 (APE1) high expression

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • GossypolDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: the first day of treatment to the date that disease progression is reported; assesed up to 4 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Daping Hospital, Third Military Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Chongqing Zhongshan Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fuling Central Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Jiangjin Central Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • The Second Affiliated Hospital of Medical University Of Chongqing

    Chongqing, Chongqing Municipality, China · Recruiting

  • Three Gorges Central Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.